ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

ClinicalTrials.gov ID: NCT07221253

Public ClinicalTrials.gov record NCT07221253. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 6:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)

Study identification

NCT ID
NCT07221253
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,100 participants

Conditions and interventions

Interventions

  • Durvalumab Drug
  • Gemcitabine/Cisplatin Drug
  • Rilvegostomig Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 3, 2025
Primary completion
Jul 3, 2029
Completion
Jul 3, 2029
Last update posted
Mar 16, 2026

2025 – 2029

United States locations

U.S. sites
33
U.S. states
20
U.S. cities
27
Facility City State ZIP Site status
Research Site Birmingham Alabama 35233 Not yet recruiting
Research Site Phoenix Arizona 85054 Not yet recruiting
Research Site Tucson Arizona 85719 Not yet recruiting
Research Site Duarte California 91010 Recruiting
Research Site Orange California 92868 Not yet recruiting
Research Site Santa Monica California 90404 Not yet recruiting
Research Site Stanford California 94305-5847 Not yet recruiting
Research Site Aurora Colorado 80045 Not yet recruiting
Research Site Hartford Connecticut 06102 Not yet recruiting
Research Site New Haven Connecticut 06510 Not yet recruiting
Research Site Washington D.C. District of Columbia 20007 Not yet recruiting
Research Site Washington D.C. District of Columbia 20037 Not yet recruiting
Research Site Jacksonville Florida 32209 Not yet recruiting
Research Site Jacksonville Florida 32224 Not yet recruiting
Research Site Marietta Georgia 30060 Recruiting
Research Site Chicago Illinois 60612 Not yet recruiting
Research Site Chicago Illinois 60637 Not yet recruiting
Research Site Louisville Kentucky 40207 Not yet recruiting
Research Site Baltimore Maryland 21205 Not yet recruiting
Research Site Ann Arbor Michigan 48109 Not yet recruiting
Research Site Detroit Michigan 48202 Not yet recruiting
Research Site Rochester Minnesota 55905 Not yet recruiting
Research Site Omaha Nebraska 68198-5885 Not yet recruiting
Research Site Santa Fe New Mexico 87505 Recruiting
Research Site New York New York 10016 Not yet recruiting
Research Site New York New York 10032 Not yet recruiting
Research Site New York New York 10065 Withdrawn
Research Site Portland Oregon 97239 Not yet recruiting
Research Site Philadelphia Pennsylvania 19104 Not yet recruiting
Research Site Philadelphia Pennsylvania 19111 Not yet recruiting
Research Site Pittsburgh Pennsylvania 15212 Not yet recruiting
Research Site Providence Rhode Island 02903 Not yet recruiting
Research Site Sioux Falls South Dakota 57105 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 135 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07221253, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 16, 2026 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07221253 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →